AKAnuradha Kaistha

Anuradha Kaistha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anuradha Kaistha has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Abel Martin Garrido

    Section of Cardiorespiratory Medicine, University of Cambridge, Victor Phillip Dahdaleh Heart & Lung Research Institute , Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0BB

    2 shared publications
  • Anna Uryga

    Section of Cardiorespiratory Medicine, University of Cambridge, Victor Phillip Dahdaleh Heart & Lung Research Institute , Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0BB

    2 shared publications
  • Helle Færk Jørgensen

    Section of Cardiorespiratory Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK

    2 shared publications
  • Kirsty Foote

    Section of Cardiorespiratory Medicine, University of Cambridge, Victor Phillip Dahdaleh Heart & Lung Research Institute , Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0BB

    2 shared publications
  • Martin Richard Bennett

    University of Cambridge

    2 shared publications
  • Nichola Figg

    Section of Cardiorespiratory Medicine, University of Cambridge, Victor Phillip Dahdaleh Heart & Lung Research Institute , Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0BB

    2 shared publications

Latest Publications

  • Open Access

    A DEFINITIVE TCRBETA1/ TCRBETA2 ANTIBODY PAIR FOR DETERMINING T-CELL MONOTYPIA AS A SURROGATE FOR CLONALITY IN LYMPHOMA DIAGNOSIS IN FORMALIN FIXED PARAFFIN EMBEDDED MATERIAL

    by Anuradha Kaistha, Jinlong J. Situ, Shelley C Evans, Margaret Ashton-Key, Graham Ogg, Elizabeth J. Soilleux

    T-cell lymphomas are often histologically indistinguishable from benign T-cell infiltrates. Clonality testing is frequently required for diagnosis. It lacks the spatial context and is slow and expensive, relying on complex, multiplexed PCR reactions, interpreted by experienced scientists or pathologists. We previously published details of a pair of highly specific monoclonal antibodies against the two alternatively used, but very similar, T-cell receptor β constant regions, TCRβ1 and TCRβ2. We demonstrated the feasibility of immunohistochemical detection of TCRβ1 and TCRβ2 in formalin-fixed, paraffin-embedded (FFPE) tissue as a novel diagnostic strategy for T-cell lymphomas. Here we validate an improved pairing of TCRβ1/2 rabbit monoclonal antibodies, and demonstrate their utility for single and double immunostaining, including with a chimeric mouse anti-TCRβ2 antibody. Finally, we show that this staining is amenable to automated cell counting, permitting accurate calculation of the TCRβ2:TCRβ1 ratio.


  • Open Access

    Premature cell senescence promotes vascular smooth muscle cell phenotypic modulation and resistance to re-differentiation

    by Anuradha Kaistha, Sebnem Oc, Abel Martin Garrido, James C K Taylor, Maria Imaz, Matthew D Worssam, Anna Uryga, Mandy Grootaert, Kirsty Foote, Alison Finigan, et al.

    Aims: Human atherosclerotic plaque cells display DNA damage that if left unrepaired can promote premature cell senescence. Vascular smooth muscle cells (VSMCs) predisposed to senescence promote atherogenesis and features of unstable plaques and increase neointima formation after injury. However, how premature VSMC senescence promotes vascular disease and its effects on VSMC phenotype are unknown. Methods and results: Bulk RNA-seq of primary human VSMCs identified 126 significantly up- or down-regulated genes after both DNA damage-induced (D + R) or replicative senescence (RS). Up-regulated genes included senescence markers CDKN2A (p16) and ICAM1 and genes expressed by phenotypically modulated de-differentiated/’fibromyocytic’ VSMCs [osteoprotegerin (TNFRSF11B), fibromodulin (FMOD)] as well as transmembrane protein 178B (TMEM178B) and secreted frizzle-related protein 4 (SFRP4). Mouse VSMCs also up-regulated genes associated with de-differentiated VSMC phenotype, Tmem178b and Sfrp4 after D + R. Single-cell RNA-sequencing of lineage-traced VSMCs in mouse plaques or human plaques showed that VSMCs expressing Cdkn2a had lower contractile marker expression and higher expression of de-differentiated VSMC markers. Mice expressing a VSMC-restricted mutant telomere protein (TRF2T188A) that induces premature senescence showed increased atherosclerosis, expression of multiple de-differentiation genes in plaques and after injury, and differential regulation of pathways associated with extracellular matrix organization, inflammation and Transforming Growth Factor-β (Tgfb). Trf2T188A VSMCs were more resistant to re-differentiation and had dysregulated Tgfb signalling at multiple levels with down-regulated ligands, receptors, and coactivators and up-regulated co-repressor expression. Trf2T188A VSMCs also showed cytosolic DNA and activation of the STING–TBK1–IRF3 pathway that suppressed Tgfb signalling. Silencing IRF3 restored expression of Tgfb pathway components and VSMC contractile markers after TGFb administration. Conclusion: DNA damage and senescence induce genes associated with de-differentiated/fibromyocytic VSMCs, and persistence of these cells in vivo. Failure of senescent VSMCs to re-express contractile markers during re-differentiation suggests that VSMC senescence may promote atherosclerosis and neointima formation in part by inhibiting their re-differentiation.


  • Open Access

    Efficacy and limitations of senolysis in atherosclerosis

    by Abel Martin Garrido, Anuradha Kaistha, Anna K Uryga, Sebnem Oc, Kirsty Foote, Aarti Shah, Alison Finigan, Nichola Figg, Lina Dobnikar, Helle Jørgensen, et al.

    Traditional markers of cell senescence including p16, Lamin B1, and senescence-associated beta galactosidase (SAβG) suggest very high frequencies of senescent cells in atherosclerosis, while their removal via ‘senolysis’ has been reported to reduce atherogenesis. However, selective killing of a variety of different cell types can exacerbate atherosclerosis. We therefore examined the specificity of senescence markers in vascular smooth muscle cells (VSMCs) and the effects of genetic or pharmacological senolysis in atherosclerosis. We examined traditional senescence markers in human and mouse VSMCs in vitro, and in mouse atherosclerosis. p16 and SAβG increased and Lamin B1 decreased in replicative senescence and stress-induced premature senescence (SIPS) of cultured human VSMCs. In contrast, mouse VSMCs undergoing SIPS showed only modest p16 up-regulation, and proliferating mouse monocyte/macrophages also expressed p16 and SAβG. Single cell RNA-sequencing (scRNA-seq) of lineage-traced mice showed increased p16 expression in VSMC-derived cells in plaques vs. normal arteries, but p16 localized to Stem cell antigen-1 (Sca1)+ or macrophage-like populations. Activation of a p16-driven suicide gene to remove p16+ vessel wall- and/or bone marrow-derived cells increased apoptotic cells, but also induced inflammation and did not change plaque size or composition. In contrast, the senolytic ABT-263 selectively reduced senescent VSMCs in culture, and markedly reduced atherogenesis. However, ABT-263 did not reduce senescence markers in vivo, and significantly reduced monocyte and platelet counts and interleukin 6 as a marker of systemic inflammation. We show that genetic and pharmacological senolysis have variable effects on atherosclerosis, and may promote inflammation and non-specific effects respectively. In addition, traditional markers of cell senescence such as p16 have significant limitations to identify and remove senescent cells in atherosclerosis, suggesting that senescence studies in atherosclerosis and new senolytic drugs require more specific and lineage-restricted markers before ascribing their effects entirely to senolysis. Effects of p16-induced genetic senolysis or ABT-263 drug-induced senolysis on atherosclerosis.